Cetuximab-induced MET activation acts as a novel resistance mechanism in colon cancer cells.
about
c-Met as a Target for Personalized TherapyPathophysiological mechanisms of death resistance in colorectal carcinomaOncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancerPharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyondA randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapyRANKL/RANK pathway abrogates cetuximab sensitivity in gastric cancer cells via activation of EGFR and c-Src.Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers.Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling.Dual inhibition of MET and SRC kinase activity as a combined targeting strategy for colon cancer.CXCL12/SDF-1α induces migration via SRC-mediated CXCR4-EGFR cross-talk in gastric cancer cellsDeep Phospho- and Phosphotyrosine Proteomics Identified Active Kinases and Phosphorylation Networks in Colorectal Cancer Cell Lines Resistant to Cetuximab.A novel function of hepatocyte growth factor in the activation of checkpoint kinase 1 phosphorylation in colon cancer cells.Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer.ZEB1 inhibition sensitizes cells to the ATR inhibitor VE-821 by abrogating epithelial-mesenchymal transition and enhancing DNA damage.IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.
P2860
Q26775483-35413AC3-7E93-4ACB-8D81-B1A906CD594EQ26778007-389D2DD9-07F8-4412-AF42-FEA42475B74EQ28077545-DC681D16-9B40-40B5-9E69-32DA8C6641E3Q28080730-34E5AA53-A9AD-43A0-994A-4FA50E56345BQ37352435-F6B5566D-A284-4C31-B414-7C817E884B7BQ37582762-77DF465A-0AD8-418D-B6FF-0DED545D78F7Q38835146-FB931422-B7E8-4A3C-B3C6-DEE39A523017Q39816968-8C7F35E9-1175-42ED-B5C8-2EBF45F4F608Q41116584-2DB87420-A5FE-41A0-99DA-F5E27516508AQ41144896-3CBF397A-AD01-4D54-9831-9439918ED613Q41620292-A8281C31-14C4-45EB-BA44-14B05E330D0FQ42510556-74C8C80B-0BC5-4C36-A81E-29871FFD7673Q42696314-F4FCA0DC-37D5-4E59-96C9-BA88D339A717Q52565789-D0FED2AB-BD98-4F4E-AB1E-E3E76C32811DQ52744136-5D6AE2E2-4FE2-493A-9AFE-AB9EC97106C9Q53258023-CE167348-4C2F-402C-92C3-7F5D06608735
P2860
Cetuximab-induced MET activation acts as a novel resistance mechanism in colon cancer cells.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Cetuximab-induced MET activati ...... chanism in colon cancer cells.
@ast
Cetuximab-induced MET activati ...... chanism in colon cancer cells.
@en
Cetuximab-induced MET activati ...... chanism in colon cancer cells.
@nl
type
label
Cetuximab-induced MET activati ...... chanism in colon cancer cells.
@ast
Cetuximab-induced MET activati ...... chanism in colon cancer cells.
@en
Cetuximab-induced MET activati ...... chanism in colon cancer cells.
@nl
prefLabel
Cetuximab-induced MET activati ...... chanism in colon cancer cells.
@ast
Cetuximab-induced MET activati ...... chanism in colon cancer cells.
@en
Cetuximab-induced MET activati ...... chanism in colon cancer cells.
@nl
P2093
P2860
P356
P1476
Cetuximab-induced MET activati ...... chanism in colon cancer cells.
@en
P2093
Jingdong Zhang
Shizhou Liu
Xiujuan Qu
Yunpeng Liu
P2860
P304
P356
10.3390/IJMS15045838
P407
P577
2014-04-04T00:00:00Z